CTOs on the Move

Catalyst Nutraceuticals

www.catalystnutra.com

 
Catalyst Nutraceuticals is a family-owned and operated business that specializes in custom manufacturing and formulation of dietary supplements for performance nutrition and wellness brands.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Imagine Pharma

Imagine Pharma is a drug discovery and development company that focuses on innovative approaches to therapeutic drugs for diabetes and cardiovascular disease. Our agile, creative and efficient approach to drug discovery is designed to find therapeutics that significantly improve on the efficacy and safety of existing treatments.

Nova Health

Nova Healths medical professionals provide treatment for urgent care, primary care and physical therapy services throughout the Western US.

SpineCenterAtlanta

Visit the orthopedic surgeons and spine specialists at Envision Ortho, serving patients in Atlanta, Augusta, and Savannah, Georgia.

Infinity Pharmaceuticals Inc

Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.